![Headquarter of biopharmaceutical company Actelion, in Allschwil, Switzerland, Thursday, February 22, 2007. Actelion announced its financial results for the full year 2006. With total net revenue of 945.7 million Swiss francs (USD Headquarter of biopharmaceutical company Actelion, in Allschwil, Switzerland, Thursday, February 22, 2007. Actelion announced its financial results for the full year 2006. With total net revenue of 945.7 million Swiss francs (USD](https://l450v.alamy.com/450v/2p0ata7/paul-stoffels-of-johnson-and-johnson-jean-paul-clozel-ceo-of-actelion-ltd-biopharmaceutical-company-based-in-allschwil-switzerland-and-joaquin-duato-vice-president-of-johnson-and-johnson-from-left-to-right-shake-hands-thursday-jan-26-2017-at-the-actelion-headquarter-in-allschwil-switzerland-johnson-johnson-is-buying-swiss-bio-pharmaceutical-company-actelion-for-about-us-30-billion-handing-the-us-based-health-care-products-giant-a-chance-to-boost-its-presence-in-innovative-biotech-treatments-patrick-straubkeystone-via-ap-2p0ata7.jpg)
Headquarter of biopharmaceutical company Actelion, in Allschwil, Switzerland, Thursday, February 22, 2007. Actelion announced its financial results for the full year 2006. With total net revenue of 945.7 million Swiss francs (USD
Kate Jones - It was great to host Paul Stoffels, Vice-Chairman of Johnson & Johnson and Cat Oyler VP J&J Global Public Health, together with Kathy Connell at Parliament House today to
![Keen to use India's brain power, says Paul Stoffels, Chief Scientific Officer, Johnson & Johnson - The Economic Times Keen to use India's brain power, says Paul Stoffels, Chief Scientific Officer, Johnson & Johnson - The Economic Times](https://img.etimg.com/thumb/msid-50967834,width-1200,height-900,imgsize-76152,overlay-economictimes/photo.jpg)